Sysmex Europe


HemoTypeSC™ is a rapid test kit for the determination of haemoglobin type in whole blood. This is a competitive lateral flow assay incorporating monoclonal antibodies for detection of haemoglobin A, haemoglobin S, and haemoglobin C.

HemoTypeSC™ provides point-of-care determination of haemoglobin phenotypes HbAA (normal), HbSS and HbSC (sickle cell disease), HbCC (haemoglobin C disease), and HbAS and HbAC (carrier or trait). HemoTypeSC™ does not detect other haemoglobin variants (such as Hb D or E) – these variants will give the same result as Hb A.

HemoTypeSC™ does not detect – and results are not affected by – fetal haemoglobin, and is therefore suitable for newborn screening.

Sickle cell disease (SCD) is a genetic condition that is present at birth. It is inherited when a child receives two sickle cell genes – one from each parent.

1 Steele et al.: Am J Hematol. 2018 Oct 5. doi: 10.1002/ajh.25305.
2 Quinn et al.: Br J Hematol. 2016 Nov; 175(4):724-73
Technical specifications
Intended use

HemoTypeSCTM is a rapid test kit for the determination of haemoglobin (Hb) type in whole blood

Assay principle 

Competitive lateral flow assay

Antibody type


Sample preparation

Whole blood

Sample type

EDTA, finger prick. heel stick, dried blood spots

Sample volume


Storage & stability

Unopened: 15-40oC for 2 years

Opened: 30 days

Type of result


Separate Liquid Buffer



Limit of Detection for

Haemoglobins A, S, and C

<2%, <2%, & <2%, respectively.

Time to result

5-10 minutes

Interference by fetal haemoglobin


Suitable for newborn screening


Test procedure

2-step procedure 

Requirement for an instrument


Sensitivity (for all phenotypes)

≥98% in field conditions2,3,4


≥98% in field conditions2,3,4

Overall diagnostic accuracy

>98% in field conditions3

Internal controls

Internal control

Pack size

50 tests including 50 blood sampling devices and 3 dropper pipettes

3 Mukherjee M, Colah R et al. Multicentre Evaluation of HemoTypeSC as  a Point-of-Care Sickle Cell Disease Rapid Diagnostic test or New-borns and  Adults Across India. Am J Clin Pathol. 2019; 1-6.
4 Nakanja R et al. HemoTypeSC demonstrated >99% field accuracy in a sickle cell disease screening initiative in children of south-eastern Uganda. Am J Hematol. 2019; 1-3

Sysmex Europe SE

Bornbarch 1

22848 Norderstedt


+49 (40) 527 26 0

+49 (40) 527 26 100


Access the training course "HemoTypeSC™ – A Rapid Point-of-Care Test for Haemoglobins That Cause Sickle Cell Disease" on the Sysmex Academy portal here.


Product documents

Regulatory Documents

Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:

Go to My Sysmex
Copyright © Sysmex Europe SE. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.